Urology/Andrology
Boji Pharmaceuticals has deepened its expertise in urology and andrology, efficiently completing over a thousand clinical trials of PDE5 inhibitors for ED treatment. These trials span all phases from Phase I to Phase III, accelerating the development of innovative drugs.
INTRODUCTION
Urology/Andrology addresses health issues related to the male reproductive and urinary systems, such as erectile dysfunction (ED). ED significantly impacts the quality of life for a large number of men, causing psychological stress and potentially indicating underlying cardiovascular disease or other health concerns. PDE5 inhibitors are currently the primary class of drugs used to treat ED, with their efficacy widely recognized.
Boji Pharmaceuticals has efficiently completed multiple Phase I, II, and III clinical trials for PDE5 inhibitor drugs treating ED, with a cumulative case count exceeding 1,000. The company possesses proficient expertise in operating the RigiScan Plus device and provides professional AVSS report analysis, fully demonstrating the therapeutic advantages of the drugs.
Clinical Research Project Experience
- Erectile dysfunction (ED)
PROJECT EXPERIENCE
Assisted in the successful approval and market launch of the Class 1 new drug Semaglutide Hydrochloride Tablets.
As the clinical research CRO for the Semaglutide Hydrochloride Tablets project, Boji Pharmaceutical was responsible for the entire Phase III clinical research process and the subsequent long-term safety trial conducted after Phase III. The approval of this drug highlights Boji Pharmaceutical's exceptional R&D service capabilities and high-quality, efficient clinical operations in organizing multi-center, large-sample, and highly complex clinical research for innovative drugs.